1. Scrip
  2. >>R&D
  3. >>Clinical Trials

As CAR-T Therapies Move Into Earlier Lines, Best Uses Begin To Come Into Focus

Yescarta, Breyanzi Second-Line LBCL Approvals Expected Soon

 
• By Mandy Jackson

Cost, logistics and safety could limit use of CAR-T therapies in first- and second-line treatment of hematologic malignancies, but for some patients there are clear benefits over standards of care.

Double escalator going up
CAR-T therapies are moving up from third-line or later into second-line and earlier settings • Source: Alamy

Chimeric antigen receptor T-cell (CAR-T) therapies have been a welcome addition to the treatment paradigm for patients with relapsed and refractory multiple myeloma and large B-cell lymphoma (LBCL) who have gone through several prior rounds of treatment and run out of good options. But within the next few months CAR-T therapies may take their first steps into earlier lines of treatment, raising the question of how physicians will adapt to use of these complex and costly treatments in new settings.

Gilead Sciences, Inc. is slated to get a decision from the US Food and Drug Administration by 1 April regarding its supplemental biologics license application (sBLA) for Yescarta (axicabtagene...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from R&D

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.